Description: Aptamer Group PLC, together with its subsidiaries, provides binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, the United States, and internationally. The company offers Optimer, a platform that enables the discovery and development of optimized DNA and RNA aptamers; and Optimer +, a platform that discovers and develops of hybrid DNA-protein molecules that combines the features of Optimer and antibodies. It serves bioprocessing and diagnostic institutes, as well as pharmaceutical scientists. The company has strategic partnership with Unilever for the development of Optimer for use in deodorant, Neuro-Bio to develop reagents for Alzheimer's disease test, and other pharma partner and AztraZeneca for drug delivery vehicle for fibrotic liver. The company was founded in 2008 and is headquartered in York, the United Kingdom.
Home Page: aptamergroup.com
Windmill House
York,
YO10 5BR
United Kingdom
Phone:
44 19 0421 7404
Officers
| Name | Title |
|---|---|
| Dr. Arron Craig Tolley | CEO & Director |
| Dr. David Bunka | Chief Scientific Officer & Executive Director |
| Mr. Andrew Mark Rapson | CFO, Company Secretary & Director |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7962 |
| Price-to-Sales TTM: | 7.9585 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 34 |